Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Accumulated Expenses (2020 - 2021)

Design Therapeutics' Accumulated Expenses history spans 2 years, with the latest figure at $941000.0 for Q2 2021.

  • On a quarterly basis, Accumulated Expenses changed N/A to $941000.0 in Q2 2021 year-over-year; TTM through Jun 2021 was $941000.0, a N/A change, with the full-year FY2020 number at $565000.0, changed N/A from a year prior.
  • Accumulated Expenses hit $941000.0 in Q2 2021 for Design Therapeutics, down from $1.7 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for DSGN hit a ceiling of $1.7 million in Q1 2021 and a floor of $565000.0 in Q4 2020.